Samad Nozlena Abdul, Abdul Ahmad Bustamam, Rahman Heshu Sulaiman, Rasedee Abdullah, Tengku Ibrahim Tengku Azmi, Keon Yeap Swee
UPM-MAKNA, Cancer Research Laboratory, Institute of Bioscience, Universiti Putra, Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
Integrative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200 Kepala Batas, Penang, Malaysia.
Pharmacogn Mag. 2018 Jan;13(Suppl 4):S731-S736. doi: 10.4103/pm.pm_18_17. Epub 2018 Jan 31.
Due to increase in the number of patients with impaired immunity, the incidence of liver cancer has increased considerably.
The aim of this study is the investigation the anticancer effect of zerumbone (ZER) on hepatocellular carcinoma (HCC).
The anticancer mechanism of ZER was determined by the rat aortic ring, human umbilical vein endothelial cells (HUVECs) proliferation, chorioallantoic membrane, cell migration, and proliferation inhibition assays.
Our results showed that ZER reduced tube formation by HUVECs effectively inhibits new blood vessel and tissue matrix formation. Western blot analysis revealed that ZER significantly ( < 0.05) decreased expression of molecular effectors of angiogenesis, the matrix metalloproteinase-9, vascular endothelial growth factor (VEGF), and VEGF receptor proteins. We found that ZER inhibited the proliferation and suppressed migration of HepG2 cell in dose-dependent manner.
Statistical analyses were performed according to the Statistical Package for Social Science (SPSS) version 17.0. The data were expressed as the mean ± standard deviation and analyzed using a one-way analysis of variance. A < 0.05 was considered statistically significant.
The study for the first time showed that ZER is an inhibitor angiogenesis, tumor growth, and spread, which is suggested to be the mechanisms for its anti-HCC effect.
Tumor angiogenesis has currently become an important research area for the control of cancer growth and metastasis. The current study determined the effect of zerumbone on factors associated with angiogenesis that occurs in tumor formation. ZER: Zerumbone, MMP-9: Matrix metalloproteinase-9, VEGF: Vascular endothelial growth factor, VEGFR: Vascular endothelial growth factor receptor, HUVECs: Human umbilical vein endothelial cells, HCC: Hepatocellular carcinoma, HIFCS: Heat inactivated fetal calf serum, DMSO: Dimethyl sulfoxide, EDTA: Ethyldiaminetetraacetic acid, Ig: Immunoglobulin, CAM: Chorioallantoic membrane, HRP: Horseradish peroxidase, NIH: National Institutes of Health, MTT: Microtetrazolium, SPSS: Statistical Package for Social Science.
由于免疫功能受损患者数量增加,肝癌发病率显著上升。
本研究旨在探究姜酮(ZER)对肝细胞癌(HCC)的抗癌作用。
通过大鼠主动脉环、人脐静脉内皮细胞(HUVECs)增殖、绒毛尿囊膜、细胞迁移和增殖抑制试验来确定ZER的抗癌机制。
我们的结果表明,ZER有效减少HUVECs形成管腔,抑制新血管和组织基质形成。蛋白质印迹分析显示,ZER显著(<0.05)降低血管生成分子效应物、基质金属蛋白酶-9、血管内皮生长因子(VEGF)和VEGF受体蛋白的表达。我们发现ZER以剂量依赖性方式抑制HepG2细胞的增殖并抑制其迁移。
根据社会科学统计软件包(SPSS)17.0版进行统计分析。数据以平均值±标准差表示,并采用单因素方差分析进行分析。P<0.05被认为具有统计学意义。
该研究首次表明,ZER是一种血管生成、肿瘤生长和扩散的抑制剂,这被认为是其抗HCC作用的机制。
肿瘤血管生成目前已成为控制癌症生长和转移的重要研究领域。当前研究确定了姜酮对肿瘤形成过程中与血管生成相关因素的影响。ZER:姜酮,MMP-9:基质金属蛋白酶-9,VEGF:血管内皮生长因子,VEGFR:血管内皮生长因子受体,HUVECs:人脐静脉内皮细胞,HCC:肝细胞癌,HIFCS:热灭活胎牛血清,DMSO:二甲基亚砜,EDTA:乙二胺四乙酸,Ig:免疫球蛋白,CAM:绒毛尿囊膜,HRP:辣根过氧化物酶,NIH:美国国立卫生研究院,MTT:噻唑蓝,SPSS:社会科学统计软件包